Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Pharma

As the Biden administration leans into the Cancer Moonshot 2.0, the life sciences industry has the opportunity to launch a new era of precision oncology. How can we accelerate progress toward truly personalized medicine and revolutionize cancer care?

Chief Strategy Officer, COTA, Inc.

Overheard at the J.P. Morgan Healthcare Conference

Executives detailed plans to take on more risk, build on advances in life sciences, and expressed optimism in Medicare Advantage, despite missing enrollment targets.

And How Stakeholders Can, Literally, Save the World

Climate change will be the biggest impact on global health. The healthcare industry may not respond in time.

Director, Marsh & McLennan Advantage Insights
Partner, Health and Life Sciences, Oliver Wyman

Social distancing may be necessary for two years or more. Here's where remote care comes into play.

Partner and CMO, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

In our rearview mirror is a ten-year stretch of experimentation. What looms ahead is the rewriting of healthcare's rules.

Partner, Health and Life Sciences, Oliver Wyman
Former Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe

A closer look at how fast change may happen, who could win (and lose), and how the next decade may unfold for incumbents and new market entrants.

Partner, Health and Life Sciences, Oliver Wyman
Senior Knowledge Expert, Oliver Wyman

Our most popular articles of the year offered our predictions on disruption and the future market, and highlighted our views on healthcare reform, ACOs, and much more.

Purposeful collaboration will help more people understand how their daily decisions dictate their health.

Director, Oliver Wyman Health Innovation Center, Oliver Wyman

Advice on how the healthcare industry can address the pharmaceutical cost problem.

Director, Marsh & McLennan Advantage, Healthcare

In light of breaking news, the pharma value chain is definitely ripe for disruption. Here's how health plans, employers, and drug companies can adjust to the new normal.

Partner, Health and Life Sciences, Oliver Wyman
Managing Partner, Americas, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe